Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.…
BBNX & SENS Launch Eversense 365 Integration With iLet Bionic Pancreas
Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration
Beta Bionics (NASDAQ: BBNX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 420 employees.
The shares were at 13.36 USD on 20 November 2026, down 51.8% over 52 weeks. Its 52-week range is 8.800 USD to 32.71 USD: the price is 59.2% below the high and 51.8% above the low.
Its market capitalisation is 726.34M USD.
Beta Bionics reports return on equity of -25.5%, an operating margin of -72.7% and revenue up 30.3% year over year.
It holds more cash than debt, a net cash position of 234.10M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 14 analysts cover the stock, with an average rating of Buy; their mean price target of 25.10 USD is 87.9% above the current price. The next earnings report is expected on 16 February 2027.